BR0315889A - Method of treating, preventing or controlling macular degeneration and pharmaceutical composition - Google Patents
Method of treating, preventing or controlling macular degeneration and pharmaceutical compositionInfo
- Publication number
- BR0315889A BR0315889A BR0315889-6A BR0315889A BR0315889A BR 0315889 A BR0315889 A BR 0315889A BR 0315889 A BR0315889 A BR 0315889A BR 0315889 A BR0315889 A BR 0315889A
- Authority
- BR
- Brazil
- Prior art keywords
- macular degeneration
- treating
- preventing
- pharmaceutical composition
- controlling
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 208000002780 macular degeneration Diseases 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"MéTODO DE TRATAR, PREVENIR OU CONTROLAR DEGENERAçãO MACULAR E COMPOSIçãO FARMACêUTICA". São descritos métodos de tratamento, prevenção e/ou controle de degeneração macular. Modalidades específicas incluem a administração de uma droga inibitória de citocina seletiva, ou de um sal, solvato, hidrato, estereoisómero, clatrato, ou pró-droga farmaceuticamente aceitáveis da mesma, sozinha ou em combinação com um segundo agente ativo e/ou cirurgia. Também são descritas composições farmacêuticas, formas de dosagem unitárias individuais, e kits adequados para uso nos métodos da invenção."METHOD OF TREATING, PREVENTING OR CONTROLING MACULAR DEGENERATION AND PHARMACEUTICAL COMPOSITION". Methods of treatment, prevention and / or control of macular degeneration are described. Specific embodiments include administration of a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof alone or in combination with a second active agent and / or surgery. Also disclosed are pharmaceutical compositions, individual unit dosage forms, and kits suitable for use in the methods of the invention.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42290002P | 2002-10-31 | 2002-10-31 | |
PCT/US2003/034535 WO2004041181A2 (en) | 2002-10-31 | 2003-10-31 | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0315889A true BR0315889A (en) | 2005-10-04 |
Family
ID=32312567
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0315889-6A BR0315889A (en) | 2002-10-31 | 2003-10-31 | Method of treating, preventing or controlling macular degeneration and pharmaceutical composition |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1567148A4 (en) |
JP (1) | JP2006509743A (en) |
KR (1) | KR20050062649A (en) |
CN (1) | CN1731997A (en) |
AU (1) | AU2003285107B2 (en) |
BR (1) | BR0315889A (en) |
CA (1) | CA2504263A1 (en) |
MX (1) | MXPA05004486A (en) |
NZ (1) | NZ540185A (en) |
TW (1) | TW200418455A (en) |
WO (1) | WO2004041181A2 (en) |
ZA (1) | ZA200503468B (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040091455A1 (en) * | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
US7776907B2 (en) * | 2002-10-31 | 2010-08-17 | Celgene Corporation | Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide |
CN103402980B (en) * | 2011-01-10 | 2016-06-29 | 细胞基因公司 | Phenethyl sulfone isoindoline derivative as PDE4 and/or cytokine inhibitor |
KR101908330B1 (en) | 2017-02-17 | 2018-10-16 | 인제대학교 산학협력단 | Novel anti-vascular endothelial growth factor antibody and composition for preventing or treating age-related macular degeneration comprising thereof |
EP4353315A3 (en) * | 2018-11-14 | 2024-05-15 | Smilebiotek Zhuhai Limited | Animal models, screening methods, and treatment methods for intraocular diseases or disorders |
DK3886852T3 (en) * | 2018-12-03 | 2024-04-29 | Smilebiotek Zhuhai Ltd | OCTYL GALLATE AND ESTERS THEREOF FOR USE IN THE TREATMENT AND PREVENTION OF AGE-RELATED MACULAR DEGENERATION CAUSED BY BACILLUS MEGATERIUM |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US577589A (en) * | 1897-02-23 | Valve for explosive-engines | ||
US5605914A (en) * | 1993-07-02 | 1997-02-25 | Celgene Corporation | Imides |
US5698579A (en) * | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
US5770589A (en) * | 1993-07-27 | 1998-06-23 | The University Of Sydney | Treatment of macular degeneration |
CN1265590A (en) * | 1997-07-31 | 2000-09-06 | 赛尔金有限公司 | Substituted alkanohydroxamic acid and method of reducing TNF 'alpha' levels |
WO1999058096A2 (en) * | 1998-05-11 | 1999-11-18 | Entremed, Inc. | Analogs of 2-phthalimidinoglutaric acid and their use as inhibitors of angiogenesis |
US6020358A (en) * | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
JP2000159761A (en) * | 1998-11-30 | 2000-06-13 | Yoshio Takeuchi | Fluorothalidomide |
US6667316B1 (en) * | 1999-11-12 | 2003-12-23 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
DE60315826T2 (en) * | 2002-04-19 | 2008-05-21 | Smithkline Beecham Corp. | NEW CONNECTIONS |
NZ570777A (en) * | 2002-05-17 | 2009-04-30 | Celgene Corp | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases |
JP2006510606A (en) * | 2002-10-15 | 2006-03-30 | セルジーン・コーポレーション | Methods of using selective cytokine inhibitors for treating and managing myelodysplastic syndrome and compositions comprising the same |
-
2003
- 2003-10-31 CA CA002504263A patent/CA2504263A1/en not_active Abandoned
- 2003-10-31 TW TW092130486A patent/TW200418455A/en unknown
- 2003-10-31 KR KR1020057007608A patent/KR20050062649A/en not_active Application Discontinuation
- 2003-10-31 CN CNA2003801080906A patent/CN1731997A/en active Pending
- 2003-10-31 MX MXPA05004486A patent/MXPA05004486A/en active IP Right Grant
- 2003-10-31 JP JP2004550274A patent/JP2006509743A/en active Pending
- 2003-10-31 AU AU2003285107A patent/AU2003285107B2/en not_active Ceased
- 2003-10-31 ZA ZA200503468A patent/ZA200503468B/en unknown
- 2003-10-31 BR BR0315889-6A patent/BR0315889A/en not_active IP Right Cessation
- 2003-10-31 WO PCT/US2003/034535 patent/WO2004041181A2/en active Application Filing
- 2003-10-31 EP EP03779423A patent/EP1567148A4/en not_active Withdrawn
- 2003-10-31 NZ NZ540185A patent/NZ540185A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
NZ540185A (en) | 2008-01-31 |
EP1567148A2 (en) | 2005-08-31 |
KR20050062649A (en) | 2005-06-23 |
JP2006509743A (en) | 2006-03-23 |
AU2003285107B2 (en) | 2008-01-10 |
EP1567148A4 (en) | 2010-09-15 |
WO2004041181A3 (en) | 2005-02-17 |
ZA200503468B (en) | 2006-10-25 |
MXPA05004486A (en) | 2005-07-26 |
TW200418455A (en) | 2004-10-01 |
AU2003285107A1 (en) | 2004-06-07 |
CA2504263A1 (en) | 2004-05-21 |
WO2004041181A2 (en) | 2004-05-21 |
CN1731997A (en) | 2006-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0415971A (en) | method for treating, preventing or controlling macular degeneration, and pharmaceutical composition | |
BRPI0415649A (en) | method for treating, preventing, modifying or administering pain and pharmaceutical composition | |
BRPI0416260A (en) | method for treating, preventing or controlling an asbestos-related disease or disorder and pharmaceutical composition | |
BR0315593A (en) | Method of treating, preventing, modifying or controlling pain and pharmaceutical composition | |
BRPI0510166A (en) | method for treating, preventing or controlling pulmonary hypertension, and pharmaceutical composition | |
BR0316082A (en) | Methods of treating or preventing and controlling a myeloproliferative disease, reducing or preventing an adverse effect associated with the administration of a second active agent in a patient suffering from a myeloproliferative disease and enhancing the therapeutic efficacy of a myeloproliferative disease treatment, composition. pharmaceutical and kit | |
BRPI0509400A (en) | methods for treating or preventing dysfunctional sleep, controlling dysfunctional sleep and improving time to sleep, duration of sleep or quality of sleep, or enhancing ability to get up feeling refreshed after a night's sleep, pharmaceutical composition , and, kit suitable for use in the treatment, prevention or control of dysfunctional sleep | |
BRPI0510110A (en) | method for treating, preventing or controlling pulmonary hypertension, and pharmaceutical composition | |
BRPI0519030A2 (en) | methods of treating, preventing, or controlling inflammation of the airways and of a disease or disorder of the airways or lungs, and pharmaceutical composition | |
BRPI0510167A (en) | method to treat, prevent or control pulmonary hypertension | |
BR0315315A (en) | Method for treating, preventing or controlling a myelodysplastic syndrome, method for reducing or preventing an adverse effect associated with the administration of a second active ingredient to a patient suffering from a myelodysplastic syndrome, pharmaceutical composition, single unit dosage form, and kit | |
BR0316050A (en) | Methods of treating, controlling or preventing specific cancer and disease associated with unwanted angiogenesis and reducing or preventing an adverse effect associated with the administration of a second active ingredient and with radiation therapy, hormone therapy, biological therapy, or immunotherapy in a patient. suffering from a specific cancer, pharmaceutical composition and kit | |
BR0315573A (en) | Method for treating, preventing, controlling and / or modifying pain in a patient and pharmaceutical composition. | |
BRPI0518567A2 (en) | pharmaceutical composition, uses of a pharmaceutical composition, sabcomelin or a pharmaceutically acceptable salt thereof, at least one neuroleptic agent and a combination of sabcomelin or a pharmaceutically acceptable salt thereof and at least one neuroleptic agent, parts kit for use in the treatment of a psychotic duster, method of treating a psychotic disorder, and sabcomelin or a pharmaceutically acceptable salt thereof | |
BRPI0518255A2 (en) | Methods of treating or preventing a central nervous system injury to reduce or prevent an adverse effect, and pharmaceutical composition | |
BR0315316A (en) | Methods of treating, preventing or controlling a myelodysplastic syndrome, and reducing or preventing an adverse effect associated with the administration of a second active ingredient to a patient suffering from a myelodysplastic syndrome, pharmaceutical composition, unit dosage form, and kit | |
BRPI0418742A (en) | methods of treating, preventing or controlling a myelodysplastic syndrome, reducing or preventing an adverse effect associated with the administration of a second active ingredient in a patient suffering from a myelodysplastic syndrome, pharmaceutical composition, single unit dosage form, and kit | |
BR0315931A (en) | Method of treating, preventing or controlling macular degeneration and pharmaceutical composition | |
BRPI0416275A (en) | methods of treating, controlling or preventing specific cancer and a disease associated with unwanted angiogenesis | |
BRPI0518062A (en) | use of a pde4 modulator, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, and, pharmaceutical composition | |
BRPI0409884A (en) | compounds, pharmaceutical compositions, method for treating or porphyxia of diseases, and uses of compounds and one or more compounds in combination with other pharmacologically active compounds | |
BRPI0519621A2 (en) | uses of sabcomelin, a pharmaceutical composition, at least one antimanic agent or mood stabilizer, and a combination of sabcomelin or a pharmaceutically acceptable salt thereof and at least one antimanic agent or mood stabilizer, pharmaceutical composition, kit of parts for use in the treatment of bipolar disorders, sabcomelin, and method of treatment of biopolar disorders | |
BR0315609A (en) | Method of treating, preventing, modifying or controlling pain and pharmaceutical composition | |
BRPI0409818A (en) | compounds, pharmaceutical compositions, method for the treatment or prophylaxis of diseases, and uses of compounds and one or more compounds in combination with other pharmacologically active compounds | |
BR0315889A (en) | Method of treating, preventing or controlling macular degeneration and pharmaceutical composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012. |